Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

Moser, Russell; Annis, James; Nikolova, Olga; Whatcott, Cliff; Gurley, Kay; Mendez, Eduardo; Moran-Jones, Kim; Dorrell, Craig; Sears, Rosalie C.; Kuo, Calvin; Han, Haiyong; Biankin, Andrew; Grandori, Carla; Von Hoff, Daniel D.; Kemp, Christopher J.

doi:10.1158/0008-5472.22431762.v1

can-21-4222_figure_s8_suppsf8.pdf (2.19 MB)

Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

journal contribution

posted on 2023-03-31, 05:21 authored by Russell Moser, James Annis, Olga Nikolova, Cliff Whatcott, Kay Gurley, Eduardo Mendez, Kim Moran-Jones, Craig Dorrell, Rosalie C. Sears, Calvin Kuo, Haiyong Han, Andrew Biankin, Carla Grandori, Daniel D. Von Hoff, Christopher J. Kemp

Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

Funding

Canary Foundation, Listwin Foundation, and Gregory Fund

Cancer-Cancer Research UK-Lustgarten Foundation Pancreatic Cancer Dream Team Research

History

ARTICLE ABSTRACT

This study utilizes functional genetic and pharmacological profiling of KRAS-mutant pancreatic adenocarcinoma to identify therapeutic strategies and finds that TFIIH inhibition synergizes with TRAIL to induce apoptosis in KRAS-driven pancreatic cancer.

Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

Funding

Canary Foundation, Listwin Foundation, and Gregory Fund

Cancer-Cancer Research UK-Lustgarten Foundation Pancreatic Cancer Dream Team Research

History

ARTICLE ABSTRACT

Usage metrics

Categories

Keywords

Licence

Exports